NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
621 Västernorrland

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 472 7.0% 40 0.6% 3 0.0% . . 1 0.0% 3 0.0% 6244 92.3% 6763 100.0%
ASCUS 246 38.0% 88 13.6% 20 3.1% 1 0.2% . . 9 1.4% 284 43.8% 648 100.0%
LSIL 166 37.8% 129 29.4% 33 7.5% 1 0.2% . . 1 0.2% 109 24.8% 439 100.0%
Atypical glandular cells/AGC 26 56.5% 4 8.7% 3 6.5% 6 13.0% 1 2.2% . . 6 13.0% 46 100.0%
Unclear atypia 8 72.7% 1 9.1% 1 9.1% . . . . . . 1 9.1% 11 100.0%
ASC-H 34 27.2% 21 16.8% 67 53.6% 1 0.8% . . 2 1.6% . . 125 100.0%
HSIL 13 8.8% 6 4.1% 120 81.1% 4 2.7% 2 1.4% 1 0.7% 2 1.4% 148 100.0%
Suspected Adenocarcinom . . . . . . . . . . . . 2 100.0% 2 100.0%
Squamous cell cancer . . . . . . . . 1 100.0% . . . . 1 100.0%
Totalt 965 11.8% 289 3.5% 247 3.0% 13 0.2% 5 0.1% 16 0.2% 6648 81.2% 8183 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category
Cancer:
M80703, M81403, M83803